Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-20
2009-12-08
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07629374
ABSTRACT:
The present invention relates to the use of novel derivatives of general formula (I)in whichR3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(═NH)R1 or C(═NH)NR1 radical;R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl, to treat a disease selected from the group consisting of: neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaries syndrome, syndrome X, immunodeficiency and cancer.
REFERENCES:
patent: 6916956 (2005-07-01), Shinagawa et al.
patent: 6949579 (2005-09-01), Dutruc-Rosset et al.
patent: 7019011 (2006-03-01), Lesuisse et al.
patent: 7166629 (2007-01-01), Lesuisse et al.
patent: 7196109 (2007-03-01), Lesuisse et al.
patent: 7407981 (2008-08-01), Lesuisse et al.
patent: WO 02/22601 (2002-03-01), None
patent: WO 03/028720 (2003-04-01), None
Taniguchi et al., J Biol Chem., 2001, (276) 10025-31, especially p. 10025.
Buee, L., et. al., Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative Disorders, Brain Research Reviews vol. 33, (2000) pp. 95-130.
Hesse, et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience Letters, 297, (2001) 187-190.
Hugon, et al., Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions., Drug metabolism reviews (1999), 31(3), 635-47.
Korneyev, Stress-induced tau phosphorylation in mouse strains with different brain Erk 1+2 immunoreactivity. , Neurochemical Research (1998), 23(12), 1539-1543.
Resnick, I., et. al., Targeting JNK3 for the Treatment of Neurodegenerative Disorders, , DDT, vol. 9, No. 21, (2004) 932 936.
Babin Didier
Dutruc-Rosset Gilles
Halley Franck
Lesuisse Dominique
Rooney Thomas
Aventis Pharma SA
Chung Susannah
Gupta Balaram
Shameem Golam M. M.
LandOfFree
Use of aminoindazole derivatives for the inhibition of tau... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of aminoindazole derivatives for the inhibition of tau..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of aminoindazole derivatives for the inhibition of tau... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123113